Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Stock data | 2024 | Change |
---|---|---|
Price | $35.98 | N/A |
Market Cap | $461.33M | N/A |
Shares Outstanding | 12.82M | N/A |
Employees | 82.00 | N/A |